AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06213766 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cognitive assessment
Description: Group 1: Cognitively healthy subject:~After signing the consent form, during the only visit of the study, the investigator will administer to cognitively healthy subjects two cognitive screening tests to ensure that they meet the criteria for group 1. If performance on the cognitive scales prove to be borderline or below current standards (Montreal Cognitive Assessment ≥ 26/30 and MacNair Cognitive Difficulties Self-Rating Scale ≥15) for at least one of the 2 tests, the participant will prematurely end the study and may be offered an in-depth cognitive assessment as part of routine care.~Group 2: Patients suffering from Alzheimer's disease:~After signing the consent form, during the only visit of the study, the investigator will administer to patients the Montreal Cognitive Assessment to assess cognitive status.
Study NCT06213766 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities.
Study NCT06213766 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: For every participants (group 1 and 2):~During the only visit of the study and after the intervention 1, the participants will answer questionnaires about:~* Demographic data such as age, gender, weight, height, education level;~* Lifestyle habits such as usual mode of transport, sense of direction, use of GPS device, and video game practice;~* Quality of sleep over the previous month and the previous night;~* Cognitive reserve questionnaire from Rami et al., 2011;~* Concomitant treatment and comorbidities.
Study NCT06213766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spatial navigation task with eye-tracking.
Description: For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences).
Study NCT06213766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatial navigation task with eye-tracking.
Description: For every participants (group 1 and 2):~During the only visit of the study and after interventions 1 and 2, the participants will complete the spatial navigation task with eye-tracking.~The participants will play the Sea Hero Quest video game and take on the role of the captain of a small boat that has to find its way through an aquatic environment. At the start of each level, the player is shown a map of the environment, with the boat's initial position and the buoys it must reach as quickly as possible in a set order. Once the map has been memorised, it disappears and the navigation begins.~Participants will play 6 levels of Sea Hero Quest (two training levels and four different navigation levels). This intervention will be proposed by a trained team member and participants will play on a digital tablet connected to an eye-tracker. The total duration of the task is 30 min (training phase + assessment sequences).
Study NCT06213766 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation.
Study NCT06213766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: For every participants (group 1 and 2):~During the only visit of the study and after interventions 1, 2 and 3, a state-qualified nurse will take venous samples from 3 tubes of 4ml each.~These blood samples will be frozen and stored until the end of the study when they will be analysed:~* Sample 1: plasmatic Quanterix p-tau217 assay;~* Sample 2: apolipoprotein E genotyping;~* Sample 3: measurement of plasmatic creatinine levels. Neither the cognitively healthy subjects, nor the patients, nor the clinicians in charge of the patients included will be informed of the results of these biological assays (absence of clinical interest established at the present time of the APOE genotype and the p-tau217 protein level, absence of modification of the care pathway, in adequacy to the bioethics law of August 02, 2021. Creatinine level is used in this study as an adjustment variable to interpret the p-tau217 protein level and will not be used for clinical interpretation.
Study NCT05180760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smartphone app use
Description: Smartphone app use in the active arm
Study NCT05180760 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of care
Description: Standard of care
Study NCT04892355 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Root canal irrigation
Description: Devices used during root canal irrigation
Study NCT05859724 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NM26-2198
Description: IL-4R/IL-31 bispecific antibody for subcutaneous administration
Study NCT05859724 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for NM26-2198
Study NCT04880564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 0.5mg/kg and CN401, 400mg
Description: CN1(0.5mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(400mg) will be administered orally twice daily.
Study NCT04880564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 1mg/kg and CN401, 600mg
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(600mg) will be administered orally twice daily.
Study NCT04880564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 1mg/kg and CN401, 800mg
Description: CN1(1mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study NCT04880564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 3mg/kg and CN401, 800mg
Description: CN1(3mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study NCT04880564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN1, 10mg/kg and CN401, 800mg
Description: CN1(10mg/kg) will be administered on Day 1 of each cycle (once every three weeks) for up to 12 months and CN401(800mg) will be administered orally twice daily.
Study NCT02739581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Variceal Ligation
Study NCT02739581 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Variceal Ligation
Study NCT02739581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non selective beta blocker
Study NCT02739581 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT04662554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1-mm Resolution Clinical PET camera
Description: 1-Millimeter Resolution Clinical PET System in Head and Neck Cancer (HNC) Imaging
Study NCT05371301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, Carboplatin
Description: Paclitaxel 175mg/m2 iv d1 followed by Carboplatin(AUC=5) iv d1
Study NCT05371301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: debulking surgery
Description: Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver
Study NCT05371301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: debulking surgery
Description: Remove all visible tumors and any other tissues or organs where tumor may have spread, which may include:~Uterus Fallopian tubes Omentum (tissue that covers the stomach, large intestine and other abdominal organs) Lymph nodes Diaphragm Part of the large bowel Spleen Parts of the liver
Study NCT06529185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The BREATHER
Description: The BREATHER is Light/Medium resistance inspiratory muscle trainer which has significance role in increasing inspiratory muscle strength and endurance which could result in a decreased sensation of dyspnea
Study NCT06529185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological treatment
Description: patient will receive the usually pharmacological treatment.
Study NCT05238792 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor-associated antigen-specific T cell (TAA-T)
Description: Patients will receive an infusion of partially HLA-matched TAA-T any time >1 week after completing most recent course of conventional (non-investigational) therapy for their disease. For the lymphodepletion cohort, patients will receive lymphodepletion (LD) chemotherapy >2 weeks from most recent course of conventional therapy and will nadir and recover before beginning TAA-T therapy. Patients will be enrolled to one of the following TAA-T dose levels:~BSA \<1.20 BSA ≥1.20 Dose level 1 without LD (low dose) 2x107 cells 4x107 cells Dose level 2 (LD + Low dose) 2x107 cells 4x107 cells Dose level 3 (LD + High dose) 4x107 cells 8x107 cells
Study NCT06296771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction and exercise group (D+E)
Description: The individuals within the dietary energy restriction and exercise group will be instructed to reduce their habitual energy intake by 5,000 kcal per week while taking part in physical exercise with a frequency of three sessions per week of HIIT and two sessions per week of resistance exercise throughout a duration of 8 weeks. Sessions can be performed in any order, but we will recommend alternating HIIT and resistance training days and taking the two rest days separately to allow for recovery.~The exercise programme will start the session by participating in a gentle stretching routine with the objective of reducing the effects of exercise-induced shoulder discomfort. The treatment focuses on the four main muscle groups in the upper body: the latissimus dorsi, the triceps, the rhomboid, the pectoral, and the upper trapezius. Each pose is held in the stretched position for a length of 15 seconds throughout each set, for a total of 4 sets.
Study NCT06105775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-enriched Beetroot Extract Capsule
Description: Starting from the 16th week of gestation and continuing for 22 weeks (154 days) or until delivery, whichever comes first, participants will consume a daily capsule containing beetroot extract enriched with 400 mg of sodium nitrate. Participants will maintain standard pre-eclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
Study NCT06105775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Capsule
Description: From the 16th week of gestation and lasting 22 weeks (154 days) or until delivery, participants will consume a daily capsule containing beetroot extract with the nitrate replaced by plant-based flour, design to mimic the appearance of the active capsule. Participants will maintain standard pre-eclampsia prophylaxis (acetylsalicylic acid 100mg nightly until 36 weeks of gestation and calcium carbonate 1000mg daily until delivery) and regular antihypertensive treatment.
Study NCT05894434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory Training
Description: The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
Study NCT05894434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multisensory Training
Description: The procedure involves repeatedly presenting identical visual-auditory stimuli at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°). The visual (a 500 ms flash) and auditory (500 ms broadband noise burst) stimuli are in spatial and temporal congruence.
Study NCT05894434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unisensory Training
Description: The procedure involves repeatedly presenting identical auditory stimuli (500 ms broadband noise burst) at a single location in the hemianopic field (initially at 45° of eccentricity along the azimuth) while the patient maintains central fixation (0°, 0°).
Study NCT05077787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage therapy
Description: Massage therapy includes stroking, kneading, rolling, tapping, vibration and effleurage over the face, chest ,abdomen and back. Massage therapy will be given for 5 minutes and will be repeated twice.
Study NCT05077787 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinaesthetic stimulation
Description: Kinaesthetic stimulation includes passive flexion and extension movements of shoulder joint, elbow joint, hip joint, knee joint and both lower limbs together. It will be given for 5 minutes in each intervention
Study NCT05539573 — intervention group
Intervention type: DEVICE
Intervention: Planned TAVI with the ACURATE neo2™ aortic bioprosthesis and ACURATE neo2™ transfemoral delivery system.
Description: The study will collect data from patients treated with the ACURATE neo2™ and its transfemoral delivery system following standard TAVI practice at each participating center. All patients will be followed to 12 months after the implant procedure. The study is divided into three periods:~1. Screening period: from screening to enrollment if study criteria are met.~2. Implantation procedure: immediately pre-implant to 24 hours post-procedure.~3. Follow-up period: at hospital discharge, at 30 days and at 12 months post-procedure.
Study NCT04962126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab 25 MG/1 ML Intravenous Solution
Description: For intravenous infusion during:~Induction phase: Day 1, 8 and 15 of cycle 1 \& Day 1 of cycle 2-6 (q3/52); Maintenance phase: Day 1 of each cycle (q8/52) for up to 12 cycles.
Study NCT04962126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 MG/40mL Intravenous Solution
Description: For intravenous infusion during induction phase only day 1 of each cycle q3/52 for up to 6 cycles.
Study NCT04962126 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 4 Gy in 2 fractions
Description: Involved site radiotherapy will only be administered to participants to achieve a PR/SD after at restaging after cycle 2, treatment will be between cycle 3 and 4 of induction treatment.
Study NCT06095726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peppermint Inhalation
Description: The researcher applied two drops (0,2ml) of 2% essential oil of peppermint on a piece of cotton. Then, each child was instructed to take three breaths of the essence that had been put on a piece of cotton before starting chemotherapy session with three minutes. In addition, the piece of cotton with peppermint essence was kept at bed side table to use by child as needed throughout the chemotherapy session. Inhalation of peppermint essence was applied for three consecutive chemotherapy sessions.
Study NCT06095726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swedish Massage
Description: Children were received Swedish massage therapy for twenty minutes prior to chemotherapy session in a private and special room with effleurage, petrissage, friction, and tapotement and vibration movements for three consecutive chemotherapy sessions. The researcher applied facilitating olive oil in hands and pre warmed before applying massage. The massage technique was applied in prone position with mild to moderate pressure with guidance by the child's feedback and tolerance by using non-scented olive oil. Children's privacy was considered.
Study NCT04769427 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDO max threads
Description: To determine the effects of absorbable Polydioxanone (PDO) thread non-surgical rhinoplasty on quality of life (FACE-Q scale)
Study NCT06372925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: 20mg atorvastatin PO
Study NCT06372925 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: 20mg atorvastatin PO
Study NCT06372925 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS/OCT
Description: performed the IVUS/OCT at baseline and Day 360
Study NCT06372925 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS/OCT
Description: performed the IVUS/OCT at baseline and Day 360
Study NCT06372925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inclisiran
Description: Inclisiran 284mg SC
Study NCT06513299 — intervention group
Intervention type: DEVICE
Intervention: low tidal volume
Description: Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 6.0 ml/kg PBW and 8.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio > 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
Study NCT06513299 — intervention group
Intervention type: DEVICE
Intervention: high tidal volume
Description: Patients ventilated with assist/control modes of mechanical ventilation with tidal volume between 8.0 ml/Kg PBW and 10.0 ml/kg PBW with PPLAT ≤ 30 cmH2O, until weaning criteria are met: P/F ratio > 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
Study NCT06513299 — intervention group
Intervention type: DEVICE
Intervention: low driving pressure
Description: Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 7.0 cmH2O and 12.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio > 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
Study NCT06513299 — intervention group
Intervention type: DEVICE
Intervention: high driving pressure
Description: Patients ventilated with assist/control modes of mechanical ventilation with driving pressure between 12.0 cmH2O and 18.0 cmH2O with VT ≤ 10 ml/kg PBW, until weaning criteria are met: P/F ratio > 250 mmHg; PEEP ≤ 8 cmH2O and lower than the previous day; FiO2 \< 0.5 and lower than the previous day; systolic arterial pressure ≥ 85 mmHg.
Study NCT06062901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational intervention
Study NCT06062901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in one-on-one interview
Study NCT06062901 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT05520047 — intervention group
Intervention type: BEHAVIORAL
Intervention: COVID19-severe Patient
Description: Behavioral and social test assessment
Study NCT05520047 — intervention group
Intervention type: BEHAVIORAL
Intervention: family of COVID19-severe Patient
Description: Behavioral and social test assessment
Study NCT06580678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH001
Description: topical application of KH001
Study NCT06580678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical application of Water for Injection
Study NCT05146219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TY-9591 Tablets
Description: TY-9591 Tablets 160mg/d
Study NCT04903288 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Eladocagene Exuparvovec
Description: Four 0.08 milliliters (mL) infusions at a dose of 0.45×10\^11 vg and a volume of 80 microliters (μl) per site to 4 sites (2 per putamen), for the total dose of 1.8×10\^11 vg and a total volume of 320 μl per participant.
Study NCT04867369 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 20mL 0.5%
Description: Interscalene nerve block with 20 mL 0.5% bupivacaine.